Home/Pipeline/Lu AG09222

Lu AG09222

Post-Traumatic Stress Disorder (PTSD)

Phase 2ActiveNCT identifier for FOCUS study

Key Facts

Indication

Post-Traumatic Stress Disorder (PTSD)

Phase

Phase 2

Status

Active

Company

Lundbeck

About Lundbeck

Lundbeck is a Danish, publicly-traded biopharmaceutical leader with a century-long legacy, exclusively focused on central nervous system (CNS) disorders. Its strategy as a 'Focused Innovator' leverages deep, accumulated expertise in neuroscience to navigate the complexities of CNS drug development and commercialization. The company has built a significant global commercial footprint, particularly in the U.S., and maintains a robust pipeline aimed at addressing high-unmet-need conditions in psychiatry, neurology, and neuro-rare diseases, underpinned by a strong financial position with a market valuation of approximately $39 billion.

View full company profile

Therapeutic Areas

Psychiatry Neurology Neuro-rare Diseases

Other Post-Traumatic Stress Disorder (PTSD) Drugs

Drug	Company	Phase	Status
AL001	Alzamend Neuro	Preclinical	Research
PES200	Virpax Pharmaceuticals	Discovery/Preclinical	Active
NeuroDirect™ Ketamine	Psycheceutical Bioscience	Phase 1	Active
Sana Device for PTSD	Sana Health	Pilot/Proof-of-Concept	Active
MDMA-assisted therapy	Lykos Therapeutics	Phase 3	Active
Neuroplastogen Programs	Delix Therapeutics	Pre-clinical	Active
TSND-201 (Methylone)	Transcend Therapeutics	Phase 2	Active
Phoenix CR	Evren Technologies	Unknown	Active
COMP360 Psilocybin Therapy	Compass Pathways	Phase 2	Active
NRX-101	NRx Pharmaceuticals	Phase 2	Investigational
Ketamir-2 (Ketamir)	MIRA Pharmaceuticals	Phase 1	Active
BNC210	Neuphoria Therapeutics	Phase 3 (planning)	Active